Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) saw an uptick in trading volume on Monday . 2,413,917 shares traded hands during mid-day trading, an increase of 94% from the previous session’s volume of 1,244,418 shares.The stock last traded at $14.2135 and had previously closed at $14.44.
Analysts Set New Price Targets
Several research firms have weighed in on BAYRY. Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 10th. Deutsche Bank Aktiengesellschaft raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research report on Thursday, July 2nd. Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a research report on Friday, May 29th. Finally, DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy”.
Check Out Our Latest Stock Analysis on Bayer Aktiengesellschaft
Bayer Aktiengesellschaft Price Performance
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.06. Bayer Aktiengesellschaft had a positive return on equity of 17.00% and a negative net margin of 3.80%.The company had revenue of $12.53 billion during the quarter, compared to the consensus estimate of $12.31 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Equities research analysts forecast that Bayer Aktiengesellschaft will post 1.28 EPS for the current year.
Bayer Aktiengesellschaft Company Profile
Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.
In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.
Further Reading
- Five stocks we like better than Bayer Aktiengesellschaft
- Fastly’s Q2 Rally Shows Investors Are Buying the Edge AI Turnaround
- Paramount’s 30-Film Promise Puts AMC Back in the Box Office Conversation
- DraftKings’ Predictions Push Could Be the Bet That Matters Most
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.
